Jefferies Initiates Braveheart Bio at Buy, Sees 75% Upside After IPO

Jefferies has initiated coverage on Braveheart Bio with a Buy rating and a $48 price target, suggesting approximately 75% upside from the biopharmaceutical company's previous closing price. The positive outlook follows Braveheart's recent initial public offering (IPO), which was one of the largest biotech debuts of 2026.

The Bull Case for BHB-1893

At the core of the investment bank's thesis is Braveheart's lead drug candidate, BHB-1893, an oral cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy (HCM). Jefferies analysts, led by Andrew Tsai, stated in a note that the drug "could offer superior attributes" compared to existing treatments from Bristol Myers Squibb and Cytokinetics.

The analysts highlighted promising Phase II data from Braveheart's partner, Hengrui, which developed the drug. The study showed BHB-1893 achieved a 76% reduction in a key obstruction measure by week 12, with 86% of patients reaching normalized heart flow. Jefferies noted this was "better than 49-57% in BMY/CYTK’s Phase IIIs after Week 24," and that responders showed no clinically significant reduction in heart pump function.

Valuation and Market Opportunity

Jefferies' valuation is based on a sum-of-the-parts discounted cash flow analysis for HCM, a progressive heart condition affecting over 700,000 patients in the U.S. For non-obstructive HCM, the bank believes the drug "could be a best-in-class asset, justifying $2-3B in sales."

The firm's $48 price target is broken down as follows:

Ad

• $27 per share for non-obstructive HCM, based on $2-3 billion in peak sales and a 25%-35% probability of success.
• $15 per share for obstructive HCM, based on $1.5-2 billion in peak sales and a 20%-30% probability of success.
• $4 per share for a potential heart failure indication, with over $1 billion in sales and a 10% probability of success.

Jefferies' upside scenario for the stock is $125 per share, while its downside case is $6.

Context and Key Catalysts

Braveheart Bio went public earlier this month, pricing its IPO at $18 per share and raising $382.5 million. Investors are now watching the clinical trial timeline, with a global Phase III study in obstructive HCM (LIONHEART-HCM) set to begin in the second half of 2026, with interim data expected in the second half of 2027. A separate Phase III study for non-obstructive HCM is planned to start in the first half of 2027.

Despite the positive outlook, Jefferies flagged several key risks for investors to consider. These include competition from established players, the potential for clinical data not translating from Phase II to Phase III trials, differences between Asian and non-Asian patient populations, and general regulatory hurdles.